Q1 Earnings Forecast for Acelyrin Issued By HC Wainwright

Acelyrin, Inc. (NASDAQ:SLRN) – Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Acelyrin in a report released on Tuesday, January 7th. HC Wainwright analyst E. Bodnar anticipates that the company will post earnings per share of ($0.44) for the quarter. HC Wainwright has a “Neutral” rating and a $6.00 price target on the stock. The consensus estimate for Acelyrin’s current full-year earnings is ($2.57) per share. HC Wainwright also issued estimates for Acelyrin’s Q2 2025 earnings at ($0.46) EPS, Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.52) EPS, FY2025 earnings at ($2.20) EPS, FY2026 earnings at ($2.60) EPS, FY2027 earnings at ($2.15) EPS, FY2028 earnings at ($1.58) EPS and FY2029 earnings at ($1.04) EPS.

A number of other research analysts also recently issued reports on the company. Citigroup cut their price objective on Acelyrin from $6.00 to $3.00 and set a “neutral” rating for the company in a research note on Tuesday. Wells Fargo & Company reduced their price objective on shares of Acelyrin from $15.00 to $13.00 and set an “overweight” rating for the company in a research note on Wednesday, December 11th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $9.60.

Acelyrin Stock Down 2.7 %

Shares of SLRN opened at $2.14 on Thursday. The business has a 50-day simple moving average of $4.23 and a two-hundred day simple moving average of $4.86. Acelyrin has a 52 week low of $1.91 and a 52 week high of $8.89. The stock has a market cap of $214.70 million, a price-to-earnings ratio of -0.87 and a beta of 1.94.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Millennium Management LLC grew its holdings in Acelyrin by 15.7% during the 2nd quarter. Millennium Management LLC now owns 4,642,056 shares of the company’s stock valued at $20,471,000 after buying an additional 628,528 shares in the last quarter. Geode Capital Management LLC grew its stake in Acelyrin by 30.8% during the third quarter. Geode Capital Management LLC now owns 1,651,614 shares of the company’s stock valued at $8,144,000 after acquiring an additional 388,631 shares in the last quarter. Almitas Capital LLC bought a new stake in Acelyrin in the 2nd quarter valued at $1,659,000. Acuta Capital Partners LLC bought a new stake in Acelyrin in the 3rd quarter valued at $1,795,000. Finally, Charles Schwab Investment Management Inc. lifted its stake in Acelyrin by 81.4% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 609,678 shares of the company’s stock worth $3,006,000 after purchasing an additional 273,604 shares in the last quarter. 87.31% of the stock is owned by hedge funds and other institutional investors.

About Acelyrin

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.